RxDoctor Payments Data

Wade Baggs, MD

Family Medicine · Tallahassee, FLNPI 1174050314

Payments from drug & device makers

$3,417in general payments, 2019–2025

Across 197 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$432
  • Lilly USA, LLC$430
  • Novo Nordisk$384
  • Boehringer Ingelheim$364
  • AstraZeneca$293
  • Amgen$209
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,32797%
  • Education$903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,417 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$44,460
Medicare patients
89
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$116,071
EliquisApixaban121$98,018
TrulicityDulaglutide66$73,163
JardianceEmpagliflozin43$52,058
FarxigaDapagliflozin Propanediol43$45,796
JanuviaSitagliptin Phosphate31$37,286
MounjaroTirzepatide27$33,088
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$28,376
EntrestoSacubitril/Valsartan12$19,750
RybelsusSemaglutide16$17,534
GraliseGabapentin11$15,205
Repatha SureclickEvolocumab15$11,389
Emgality PenGalcanezumab-Gnlm13$8,449
MyrbetriqMirabegron15$7,248
VascepaIcosapent Ethyl18$7,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$384$133,60598 claims
Lilly USA, LLCTrulicity, Mounjaro$430$106,25193 claims
PfizerEliquis$181$98,018121 claims
Boehringer IngelheimJardiance$364$52,05843 claims
AstraZenecaFarxiga$293$45,79643 claims
MerckJanuvia$101$37,28631 claims
GSKTrelegy Ellipta$147$28,37633 claims
NovartisEntresto$174$19,75012 claims
AbbVieSynthroid$432$1,34512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →